IPSEN Stock Price, News & Analysis (OTCMKTS:IPSEY)

$29.55 0.00 (0.00 %)
(As of 12/18/2017 01:11 PM ET)
Previous Close$29.55
Today's RangeN/A
52-Week Range$17.37 - $35.86
VolumeN/A
Average Volume336 shs
Market Capitalization$9.89 billion
P/E RatioN/A
Dividend Yield0.59%
Beta0.99

About IPSEN (OTCMKTS:IPSEY)

IPSEN logoIpsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Primary Care and Specialty Care. The company offers drugs in urology – oncology, endocrinology, neurology, gastroenterology, cognitive disorders, rheumatology, and cardiovascular areas. Its products include Decapeptyl, a synthetic hormone made of triptorelin and decapeptide analog of gonadotrophin releasing hormone, for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; Hexvix, a photosensitizing agent, for detection and resection of non invasive bladder cancer; and Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum toxin type A complex used to treat cervical dystonia, cerebral palsy, blepharospasms, and hemifacial spasms. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan for the treatment of age-related cognitive disorders. Further, the company provides Nisis and Nisisco, which are antihypertensive agents for treating hypertension; Adenuric for the treatment of gout; and Adrovance for treating post-menopausal osteoporosis. Additionally, it is developing chimeric somastatin and dopamine agonist molecule, BN82451, VSN16R, OPS201, OPS202, MCNA, and LX1032 drugs. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Receive IPSEY News and Ratings via Email

Sign-up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:IPSEY
CUSIPN/A
Phone33-01-58-33-50-00

Debt

Debt-to-Equity RatioN/A
Current Ratio1.00%
Quick Ratio0.84%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio24.42
P/E Growth1.11

Sales & Book Value

Annual Sales$1.75 billion
Price / Sales5.64
Cash Flow$1.00 per share
Price / Cash29.47
Book Value$4.51 per share
Price / Book6.55

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees4,907
Outstanding Shares334,640,000

IPSEN (OTCMKTS:IPSEY) Frequently Asked Questions

What is IPSEN's stock symbol?

IPSEN trades on the OTCMKTS under the ticker symbol "IPSEY."

How often does IPSEN pay dividends? What is the dividend yield for IPSEN?

IPSEN announced a None dividend on Friday, July 7th. Investors of record on Monday, June 12th will be given a dividend of $0.175 per share on Tuesday, July 11th. The ex-dividend date of this dividend is Thursday, June 8th. View IPSEN's Dividend History.

Who are some of IPSEN's key competitors?

How do I buy IPSEN stock?

Shares of IPSEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IPSEN's stock price today?

One share of IPSEN stock can currently be purchased for approximately $29.55.

How big of a company is IPSEN?

IPSEN has a market capitalization of $9.89 billion and generates $1.75 billion in revenue each year. IPSEN employs 4,907 workers across the globe.

How can I contact IPSEN?

IPSEN's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company can be reached via phone at 33-01-58-33-50-00 or via email at [email protected]


MarketBeat Community Rating for IPSEN (IPSEY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  132
MarketBeat's community ratings are surveys of what our community members think about IPSEN and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

IPSEN (OTCMKTS:IPSEY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.752.60
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

IPSEN (OTCMKTS:IPSEY) Consensus Price Target History

Price Target History for IPSEN (OTCMKTS:IPSEY)

IPSEN (OTCMKTS:IPSEY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
9/20/2017Societe GeneraleUpgradeHold -> BuyView Rating Details
7/7/2016J P Morgan Chase & CoDowngradeOverweight -> NeutralView Rating Details
5/9/2016Morgan StanleyUpgradeEqual Weight -> OverweightView Rating Details
4/26/2016Jefferies GroupUpgradeHold -> BuyView Rating Details
3/8/2016BarclaysDowngradeOverweight -> Equal WeightView Rating Details
(Data available from 12/18/2015 forward)

Earnings

Earnings History for IPSEN (OTCMKTS:IPSEY)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

IPSEN (OTCMKTS:IPSEY) Earnings Estimates

Current Year EPS Consensus Estimate: $1.21 EPS
Next Year EPS Consensus Estimate: $1.51 EPS

Dividends

IPSEN (OTCMKTS:IPSEY) Dividend Information

Most Recent Dividend:7/11/2017
Annual Dividend:$0.17
Dividend Yield:0.58%
Payout Ratio:14.05% (Based on This Year's Estimates)
11.26% (Based on Next Year's Estimates)
Dividend Payments by Quarter for IPSEN (OTCMKTS:IPSEY)

IPSEN (OTCMKTS:IPSEY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/7/2017None$0.186/8/20176/12/20177/11/2017
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for IPSEN (OTCMKTS IPSEY)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

IPSEN (OTCMKTS IPSEY) News Headlines

Source:
DateHeadline
Ipsen Announces Its Corporate Agenda for 2018Ipsen Announces Its Corporate Agenda for 2018
finance.yahoo.com - December 6 at 5:46 PM
Ipsen announces publication in Neurology of results of two studies demonstrating the efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with lower limb spasticityIpsen announces publication in Neurology of results of two studies demonstrating the efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with lower limb spasticity
finance.yahoo.com - November 29 at 9:04 AM
Ipsen Delivers Strong Sales Growth of 22.6%1 for the Third Quarter of 2017 and Confirms Full Year GuidanceIpsen Delivers Strong Sales Growth of 22.6%1 for the Third Quarter of 2017 and Confirms Full Year Guidance
finance.yahoo.com - October 26 at 2:30 PM
Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular CarcinomaIpsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
finance.yahoo.com - October 16 at 3:42 PM
Ipsen Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual AssemblyIpsen Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly
finance.yahoo.com - October 13 at 2:55 AM
Ipsen Joins PhRMA to Continue Advancing Research and InnovationIpsen Joins PhRMA to Continue Advancing Research and Innovation
finance.yahoo.com - October 11 at 4:43 PM
Ipsen Announces Four Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Child Neurology Society Annual MeetingIpsen Announces Four Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Child Neurology Society Annual Meeting
finance.yahoo.com - October 4 at 5:59 PM
Ipsen Receives Approval from European Commission for Xermelo® (Telotristat Ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue TherapyIpsen Receives Approval from European Commission for Xermelo® (Telotristat Ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy
finance.yahoo.com - September 19 at 7:59 PM
Societe Generale Upgrades Ipsen Sa Adr (IPSEY) to "Buy"Societe Generale Upgrades Ipsen Sa Adr (IPSEY) to "Buy"
www.americanbankingnews.com - September 19 at 1:52 PM
U.S. FDA Approves New Indication for Ipsens Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid SyndromeU.S. FDA Approves New Indication for Ipsen's Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
finance.yahoo.com - September 18 at 5:09 AM
Ipsen Announces Analysis of Managed Medicaid Data of Children with Cerebral Palsy at Annual Meeting of the American Academy of Cerebral Palsy and Developmental MedicineIpsen Announces Analysis of Managed Medicaid Data of Children with Cerebral Palsy at Annual Meeting of the American Academy of Cerebral Palsy and Developmental Medicine
finance.yahoo.com - September 16 at 2:14 AM
Ipsen Announces Oral and Poster Presentations of abobotulinumtoxinA Data at the 2017 Annual Meeting of the American Academy of Cerebral Palsy and Developmental MedicineIpsen Announces Oral and Poster Presentations of abobotulinumtoxinA Data at the 2017 Annual Meeting of the American Academy of Cerebral Palsy and Developmental Medicine
finance.yahoo.com - September 15 at 2:23 AM
Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017
finance.yahoo.com - September 9 at 7:20 PM
Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx® (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adultsIpsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx® (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults
finance.yahoo.com - September 8 at 11:51 PM
Ipsen Biopharmaceuticals Canada Names Paul Reider Country Manager and Joins Innovative Medicines Canada to Drive Development and Delivery of Key TherapiesIpsen Biopharmaceuticals Canada Names Paul Reider Country Manager and Joins Innovative Medicines Canada to Drive Development and Delivery of Key Therapies
finance.yahoo.com - September 5 at 4:44 PM
Ipsen Announces 16 Abstract Presentations of Oncology Portfolio at European Society of Medical Oncology CongressIpsen Announces 16 Abstract Presentations of Oncology Portfolio at European Society of Medical Oncology Congress
finance.yahoo.com - September 4 at 2:31 AM
Why IPSEN (IPSEY) Could Be an Impressive Growth StockWhy IPSEN (IPSEY) Could Be an Impressive Growth Stock
finance.yahoo.com - August 3 at 8:04 PM
Ipsen SA :IPSEY-US: Earnings Analysis: For the six months ended June 30, 2017 : August 1, 2017Ipsen SA :IPSEY-US: Earnings Analysis: For the six months ended June 30, 2017 : August 1, 2017
finance.yahoo.com - August 1 at 3:37 PM
Ipsen Delivers Strong Sales Growth of 18.8%1 in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017Ipsen Delivers Strong Sales Growth of 18.8%1 in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017
finance.yahoo.com - July 27 at 1:17 AM
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue TherapyIpsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy
finance.yahoo.com - July 22 at 1:58 AM
Ipsen: Somatuline® Autogel® 120 mg Receives Japanese Approval for a New Indication for the Treatment of Gastro-Entero-Pancreatic Neuroendocrine TumorsIpsen: Somatuline® Autogel® 120 mg Receives Japanese Approval for a New Indication for the Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors
finance.yahoo.com - July 3 at 7:06 AM
Ipsen Biopharmaceuticals Announces FDA Approval of DysportIpsen Biopharmaceuticals Announces FDA Approval of Dysport
www.streetinsider.com - June 17 at 11:29 PM
Midcap Biopharma Stocks Pick Up In The First QuarterMidcap Biopharma Stocks Pick Up In The First Quarter
seekingalpha.com - April 7 at 5:51 PM
Ipsen SA :IPSEY-US: Earnings Analysis: For the six months ended December 31, 2016 : April 3, 2017Ipsen SA :IPSEY-US: Earnings Analysis: For the six months ended December 31, 2016 : April 3, 2017
us.rd.yahoo.com - April 4 at 4:12 AM
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack PharmaceuticalsIpsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
uk.finance.yahoo.com - April 3 at 5:16 PM
The Ipsen Group Publishes Its 2016 Registration DocumentThe Ipsen Group Publishes Its 2016 Registration Document
www.businesswire.com - March 28 at 5:34 PM
UCB Needs Clinical Success To Drive UpsideUCB Needs Clinical Success To Drive Upside
seekingalpha.com - March 21 at 5:55 PM
Ipsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Patients with Cervical Dystonia and Adult Upper Limb SpasticityIpsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Patients with Cervical Dystonia and Adult Upper Limb Spasticity
us.rd.yahoo.com - March 14 at 11:47 AM
Ipsen announces MHRA1 approval of new indication for Decapeptyl® for the treatment of pre-menopausal women with early stage breast cancerIpsen announces MHRA1 approval of new indication for Decapeptyl® for the treatment of pre-menopausal women with early stage breast cancer
uk.finance.yahoo.com - March 13 at 10:50 AM
Ipsen Announces Data Presentations of Lanreotide (Somatuline® Autogel®), Telotristat Ethyl and the Investigational Compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 ConferenceIpsen Announces Data Presentations of Lanreotide (Somatuline® Autogel®), Telotristat Ethyl and the Investigational Compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 Conference
uk.finance.yahoo.com - March 9 at 7:19 AM
Ipsen Appoints Benoit Hennion as Executive Vice President and President, Primary CareIpsen Appoints Benoit Hennion as Executive Vice President and President, Primary Care
uk.finance.yahoo.com - March 2 at 3:28 PM
Ipsens (IPSEY) CEO David Meek on Q4 2016 Results - Earnings Call TranscriptIpsen's (IPSEY) CEO David Meek on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - February 25 at 12:15 AM
Ipsen Delivers Strong 2016 Results and Expects Further Sales Growth and Margin Enhancement for 2017Ipsen Delivers Strong 2016 Results and Expects Further Sales Growth and Margin Enhancement for 2017
uk.finance.yahoo.com - February 23 at 4:14 AM
Drugmaker Ipsen to buy some products from Sanofi for 83 million eurosDrugmaker Ipsen to buy some products from Sanofi for 83 million euros
us.rd.yahoo.com - February 13 at 11:07 AM
3:27 am Ipsen S.A. to acquire 5 of Sanofis (<a href="/q?s=sny" name="sny">SNY</a>) Consumer Healthcare Products for EUR83 mln3:27 am Ipsen S.A. to acquire 5 of Sanofi's (SNY) Consumer Healthcare Products for EUR83 mln
us.rd.yahoo.com - February 13 at 11:07 AM
Is Merrimack Pharmaceuticals Worth Stashing in Portfolios?Is Merrimack Pharmaceuticals Worth Stashing in Portfolios?
www.fool.com - February 12 at 5:49 PM
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas PharmaIpsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
uk.finance.yahoo.com - January 31 at 4:41 AM
Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global FranchisesIpsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises
uk.finance.yahoo.com - January 20 at 5:49 AM
Ipsen to acquire oncology assets from MerrimackIpsen to acquire oncology assets from Merrimack
seekingalpha.com - January 9 at 4:45 PM
Merrimack Soars on $1 Billion Sale of Cancer Drugs to IpsenMerrimack Soars on $1 Billion Sale of Cancer Drugs to Ipsen
www.thestreet.com - January 9 at 4:45 PM
Merrimack Pharma to Sell Cancer Drugs for $1BMerrimack Pharma to Sell Cancer Drugs for $1B
www.investopedia.com - January 9 at 4:45 PM
Merrimack Concludes Strategic Review; Announces Plan to Divest Assets and Sharpen Strategic FocusMerrimack Concludes Strategic Review; Announces Plan to Divest Assets and Sharpen Strategic Focus
us.rd.yahoo.com - January 8 at 10:43 PM
Ipsen to Acquire Oncology Assets from Merrimack PharmaceuticalsIpsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
us.rd.yahoo.com - January 8 at 10:43 PM
Frances Ipsen to buy some Merrimack assets for up to $1 blnFrance's Ipsen to buy some Merrimack assets for up to $1 bln
us.rd.yahoo.com - January 8 at 10:43 PM
Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include CanadaExelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada
au.finance.yahoo.com - December 21 at 8:42 AM
Ipsen Announces Its Corporate Agenda for 2017Ipsen Announces Its Corporate Agenda for 2017
uk.finance.yahoo.com - December 13 at 10:16 AM
Claude Bertrand to Step Down as Executive Vice President, R&D, Chief Scientific Officer of IpsenClaude Bertrand to Step Down as Executive Vice President, R&D, Chief Scientific Officer of Ipsen
uk.finance.yahoo.com - December 12 at 10:50 AM
Ipsen Reports 12.2%1 Sales Growth for the Third Quarter of 2016 and Raises Full Year GuidanceIpsen Reports 12.2%1 Sales Growth for the Third Quarter of 2016 and Raises Full Year Guidance
uk.finance.yahoo.com - October 26 at 8:53 AM
Exelixiss stock surges after positive results from trial of kidney cancer treatmentExelixis's stock surges after positive results from trial of kidney cancer treatment
www.marketwatch.com - June 6 at 7:47 AM

SEC Filings

IPSEN (OTCMKTS:IPSEY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

IPSEN (OTCMKTS IPSEY) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.